Free Newsletter
Lilly hungry enough for less-mega deals
Free newsletter via e-mail
Tools
Eli Lilly chief John Lechleiter may not be up for a mega-merger, but he is looking for acquisitions of as much as $15 billion now that Lilly has digested ImClone Systems. "I got hungry again about three weeks after ImClone got closed" in late November, Dr. Lechleiter told the Wall Street Journal. Report
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline
SHARE
WITH: